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OBJECTIVES We sought to determine if an underlying mechanism of the association between prolonged
symptom-to-treatment times and adverse outcomes may be an association of symptom-to-
treatment times with impaired Thrombolysis In Myocardial Infarction myocardial perfusion
grades (TMPGs).
BACKGROUND Prolonged symptom duration among ST-segment elevation myocardial infarction (STEMI)
patients undergoing fibrinolytic therapy is associated with adverse outcomes.
METHODS Angiography was performed 60 min after fibrinolytic administration in 3,845 Thrombolysis
In Myocardial Infarction (TIMI) trial patients.
RESULTS The median time from symptom onset to treatment was longer among patients with impaired
myocardial perfusion (3.0 h for TMPG 0/1 vs. 2.7 h for TMPG 2/3; p  0.001). In a
multivariate model, impaired tissue perfusion (TMPG 0/1) remained associated with
increased time to treatment (odds ratio 1.14 per hour of delay; p 0.007) even after adjusting
for Thrombolysis In Myocardial Infarction flow grade (TFG) 3, left anterior descending
infarct location, and baseline clinical characteristics. Impaired myocardial perfusion after
rescue/adjunctive percutaneous coronary intervention (PCI) was associated with longer
median times to treatment (3.0 h for TMPG 2/3 vs. 2.7 h for TMPG 0/1; p 0.017), as was
abnormal epicardial flow after rescue/adjunctive PCI (3.3 h for TFG 0/1/2 vs. 2.8 h for TFG
3; p  0.005). Thirty-day mortality was associated with longer time from onset of symptoms
to treatment (6.6% mortality for time to treatment 4 h vs. 3.3%; p  0.001), even among
patients undergoing rescue PCI.
CONCLUSIONS A prolonged symptom to treatment time among STEMI patients is associated with impaired
myocardial perfusion independent of epicardial flow both immediately after fibrinolytic
administration and after rescue/adjunctive PCI. These data provide a pathophysiologic link
between prolonged symptoms due to vessel occlusion, impaired myocardial perfusion, and
poor clinical outcomes. (J Am Coll Cardiol 2004;44:980–7) © 2004 by the American
College of Cardiology Foundationa
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Tprolonged duration of symptoms (longer “symptom to
reatment times”) among patients with ST-segment eleva-
ion myocardial infarction (STEMI) is associated with
oorer clinical outcomes (1–3). The time-dependent nature
f clinical outcomes after the administration of fibrinolytics
as been attributed previously, at least in part, to a failure to
chieve successful epicardial reperfusion among patients
reated at longer intervals from symptom onset, a concept
eferred to as “thromboresistance” (1). However, there also
ay be other mechanisms that contribute to the correlation
etween time to treatment and clinical outcomes. In an
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Manuscript received March 12, 2004; revised manuscript received May 6, 2004,1ccepted May 11, 2004.nalysis of the Stent versus Thrombolysis for Occluded
oronary arteries in Patients with Acute Myocardial Infarc-
ion (STOP-AMI) trials, Schomig et al. (4) demonstrated
hat longer symptom-to-treatment times are associated with
orsened myocardial salvage among patients treated with
brinolytic therapy.
Insofar as improved myocardial salvage has been linked to
he restoration of normal myocardial perfusion (5), the goal
f the present study was to examine the association of delays
n symptom-to-treatment times with the restoration of
yocardial as well as epicardial perfusion. We hypothesized
hat, in patients, a prolonged duration of symptoms at
resentation would be associated with impaired myocardial
erfusion after fibrinolytic administration in the setting of
TEMI.
ETHODS
linical and angiographic data were pooled from the
hrombolysis In Myocardial Infarction (TIMI)-4, TIMI-
0, TIMI-14, Integrilin and Tenecteplase in Acute Myo-
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ive Antithrombin Therapy for ST-Elevation Myocardial
nfarction (ENTIRE–TIMI-23), and Fibrinolytic and Ag-
rastat ST-Elevation Resolution (FASTER) studies in
TEMI. Briefly, the TIMI-4 trial was a randomized
ouble-blind comparison of anistreplase (Eminase, Glaxo-
mithKline, Research Triangle Park, North Carolina) ver-
us front-loaded tissue-type plasminogen activator (t-PA)
alteplase or Activase, Genetech Inc., South San Francisco,
alifornia) versus combination therapy in 416 patients (6).
he TIMI-10A trial was a nonrandomized, open-label,
ose-escalation study of eight ascending doses of tenect-
plase (TNK) (7). TIMI-10B was a randomized trial
omparing 30, 40, and 50 mg of TNK versus front-loaded
-PA (8). In the TIMI-14 trial, patients were randomized to
eceive either full-dose fibrinolytic (t-PA or reteplase
r-PA]) or abciximab in combination with a reduced dose of
brinolytic agents, which also included streptokinase (9,10).
n the INTEGRITI trial, patients were randomized to
ull-dose TNK versus combinations of eptifibatide and
educed-dose TNK (11). In ENTIRE–TIMI-23 (n 483),
atients were randomized to: 1) full-dose TNK plus unfrac-
ionated heparin, 2) full dose TNK plus enoxaparin, or 3)
alf-dose TNK plus abciximab in addition to either unfrac-
ionated heparin or enoxaparin (12). FASTER was a phase
I trial evaluating the efficacy of a combination of tirofiban,
NK, and unfractionated heparin in patients with acute
TEMI. In each of the trials, an angiography was per-
ormed at both 60 min and 90 min after the initiation of
brinolytic agents. The primary angiographic end point was
ssessed at 90 min in TIMI-4, TIMI-10, and TIMI-14 and
t 60 min in INTEGRITI, ENTIRE–TIMI-23, and
ASTER. All data reported in the present analysis are for
he 60-min time point unless otherwise specified. Rescue or
djunctive percutaneous coronary intervention (PCI) after
ndex angiography was performed at the discretion of
ndividual operators in the TIMI trials.
ssessment of flow and perfusion. Angiographic end
Abbreviations and Acronyms
CHF  congestive heart failure
CTFC  corrected Thrombolysis In Myocardial
Infarction frame count
LAD  left anterior descending
PCI  percutaneous coronary intervention
OR  odds ratio
rt-PA  recombinant tissue-type plasminogen activator
STEMI  ST-segment elevation myocardial infarction
TFG  Thrombolysis In Myocardial Infarction flow
grade
TIMI  Thrombolysis In Myocardial Infarction
TMPG  Thrombolysis In Myocardial Infarction
myocardial perfusion grade
TNK  tenecteplase
t-PA  tissue-type plasminogen activatoroints were prospectively assessed at 60 min after the 0dministration of fibrinolytics. Thrombolysis In Myocardial
nfarction myocardial perfusion grades (TMPGs), Throm-
olysis In Myocardial Infarction flow grades (TFG), and
orrected Thrombolysis In Myocardial Infarction frame
ounts (CTFCs) were assessed as defined previously (13–
5) by a single blinded observer (C.M.G.). The CTFC was
onverted when necessary to be based on the most common
lming speed in the U.S. of 30 frames per second (14).
igital subtraction angiography was performed as described
reviously, and the intensity of blush within the region of
nterest was quantitated using a grayscale standard (16).
tatistical analysis. All analyses were performed using
tata version 7.0 (Stata Corp., College Station, Texas). All
ontinuous variable values are reported as the median with
5% and 75% confidence intervals (median [25th, 75th
onfidence intervals]) unless otherwise stated. The nonpara-
etric Wilcoxon rank-sum test was used for the analysis of
ontinuous variables when they were not normally distrib-
ted. The chi-square test was used for the analysis of
ategorical variables when sample size was5 for all cells in
table. When the sample size was 5 in a given cell of a
able, the Fisher exact test was used. A multivariate model
as used to assess the association between TMPG and time
rom symptom onset to treatment, adjusting for TFG, left
nterior descending (LAD) infarct location, and baseline
linical characteristics, including TIMI risk score.
ESULTS
aseline characteristics. Among the 3,913 patients with
cute STEMI enrolled in the trials, 422 were treated with
on-fibrin-specific agents (streptokinase, anistreplase, or a
ombination of APSAC and t-PA), 1,908 were treated with
brin-specific agents alone (t-PA, rt-PA, TNK), and 1,551
atients were treated with a combination of a fibrin-specific
gent plus a glycoprotein IIb/IIIa inhibitor or a glycoprotein
Ib/IIIa inhibitor alone. Among the 3,845 patients with
vailable time of symptom onset, the median time from
nset of chest pain to fibrinolytic therapy was 2.9 h (2.1,
.2), with 26.6% of patients (1,022, 3,845) presenting 4 h
fter symptom onset (Fig. 1). Patients with shorter
ymptom-to-treatment times were younger and more likely
o be male (Table 1). In contrast, those with prolonged
ymptom-to-treatment times were more likely to be female
p 0.001) and diabetic (p 0.059). The pulse and systolic
lood pressure were higher among these patients on admis-
ion (Table 1). Patients with shorter symptom-to-treatment
imes had lower TIMI risk scores than patients with longer
ymptom-to-treatment times (p  0.001).
ngiographic data. The median time from symptom onset
o treatment was longer among patients with impaired
yocardial perfusion at 60 min (TMPG 0/1, median 3.0 h
s. 2.7 h for TMPG 2/3; p  0.001) (Fig. 2A). Likewise,
atients with a delay in symptom onset to treatment 4 h
ere less likely to have TMPG 2/3 (46.5% vs. 55.1%; p 
.04) (Fig. 2B), and the myocardium was paler on digital
s
0
a
m
a
(
h
e
t
(
5
h
h
0
T
p
S
P
a
v
1
h
p
T
a
t
0
b
l
r
1
r
a
t
P
t
i
s
w
f
5
p
0
f
s

h
(
(
A
I
t
t
w
f
T
a
h
o
w
i
3
T
p
a
C
q
F
t
T
O
T
A
A
F
P
H
H
C
P
P
S
A
T
M
T
982 Gibson et al. JACC Vol. 44, No. 5, 2004
Duration of Symptoms and Myocardial Perfusion September 1, 2004:980–7ubtraction angiography (median 6.6 vs. 8.0 gray scale; p 
.02) (Fig. 2C).
The median symptom-to-treatment time was longer
mong patients with a closed epicardial artery (TFG 0/1,
edian 3.3 h vs. 2.8 h for TFG 2/3; p  0.001) (Fig. 3A)
nd among patients with any abnormality in epicardial flow
TFG 0/1/2) vs. patients with TFG 3 (median 2.8 [2.0, 3.9]
vs. 3.0 [2.1, 4.2] h; p  0.02). Similarly, patients who
xperienced a delay in symptom onset to treatment (4 h
ime-to-treatment) were less likely to achieve TFG 2/3
71.3% vs. 79.5%; p 0.001) (Fig. 3B) or TFG 3 (47.6% vs.
2.3%, p  0.035). The median CTFC at 60 min was
igher among patients with symptom onset to treatment4
(42.9 [27.6, 100] frames vs. 38.2 [25, 100] frames; p 
igure 1. Cumulative distribution function of time from symptom onset to
reatment in hours.
able 1. Baseline Characteristics and Time From Symptom
nset to Treatment
Time to
Treatment
>4 h
(n  1022)
Time to
Treatment
<4 h
(n  2823) p Value
ime from symptom
onset to treatment, h
Median  5.3
IQ 4.6/6.7
Median  2.4
IQ 1.9/3.1
ge, yrs 59.2 11.3 57.7 10.6 0.0002
ge 65 yrs 37.1% 29.8% 0.001
emale gender 26.5% 20.7% 0.001
revious MI 11.5% 12.8% 0.279
istory of diabetes 15.4% 13.1% 0.059
istory of hypertension 33.0% 32.0% 0.552
urrent smokers 48.2% 49.8% 0.390
revious PCI 6.7% 8.2% 0.126
ulse on admission,
beats/min
78.5  18.0 74.6 17.4 0.0001
ystolic blood pressure
on admission
140.1  21.6 137.6 22.4 0.0019
nterior MI per ECG 40.5% 37.2% 0.065
IMI risk score
0–1 36.0% 64.4% 0.001
2–4 35.4% 26.1%
5 28.6% 9.5%
I  myocardial infarction; PCI  percutaneous coronary intervention; TIMI 
ohrombolysis In Myocardial Infarction..001) (Fig. 3C). Even when restricted to patients with
FG 3, the CTFC at 60 min trended higher among
atients with symptom onset to treatment 4 h (mean 
D of 27.6  9.4 frames vs. 26.4  8.7 frames; p  0.058).
atients with time from symptom onset to treatment 4 h
lso had lower ejection fractions measured during left
entriculography (mean  SD of 55.3  15.5% vs. 58.8 
4.5%; p  0.0001) (Table 2, Fig. 4A) and more frequently
ad collaterals present on the angiogram (16.1% vs. 12.4%;
 0.004) (Table 2, Fig. 4B).
In a multivariate model adjusting for TIMI risk score,
FG 3, and LAD infarct location, impaired tissue perfusion
t 60 min (TMPG 0/1) was associated with increased time
o treatment (odds ratio [OR] 1.13 per hour of delay; p 
.013). In an analysis adjusting for age, gender, pulse and
lood pressure on admission, TFG 3, and LAD infarct
ocation, impaired tissue perfusion at 60 min (TMPG 0/1)
emained associated with increased time to treatment (OR
.14 per hour of delay; p  0.007). In a similar model
estricted to patients with TFG 3, impaired tissue perfusion
t 60 min (TMPG 0/1) remained associated with increased
ime to treatment (OR 1.13 per hour of delay; p  0.049).
erfusion and flow after rescue/adjunctive PCI. Among
he 1,464 patients who underwent rescue/adjunctive PCI
mmediately after index angiography, the median time from
ymptom onset to treatment was longer among patients
ith impaired myocardial perfusion after PCI (median 3.0 h
or TMPG 0/1 vs. 2.7 h for TMPG 2/3; p  0.017) (Fig.
). The median time to treatment also was longer among
atients with TFG 3 after PCI (2.75 h vs. 3.25 h; p 
.005) (Fig. 6A). Likewise, TFG 3 was achieved less
requently after PCI among patients whose time from
ymptom onset to treatment was 4 h (81.3% vs. 87.0%; p
0.007) (Fig. 6B). The median CTFC after PCI was
igher in patients with symptom onset to treatment 4 h
24.4 [17, 37] frames vs. 22.0 [16, 32] frames; p  0.008)
Fig. 6C).
nalyses stratified by fibrin specificity and glycoprotein
Ib/IIIa inhibitor usage. In a separate analysis restricted
o patients treated with fibrin-specific fibrinolytic mono-
herapy, the median time from symptom onset to treatment
as greater among patients with impaired myocardial per-
usion (3.0 [2.0, 4.1] h for TMPG 0/1 vs. 2.6 [1.9, 3.7] h for
MPG 2/3; p 0.03) and was greater among patients with
closed epicardial artery (3.2 [2.3, 4.6] h vs. 2.8 [2.0, 3.9]
for an open artery; p  0.0002). Similar findings were
bserved among patients treated with combination therapy
ith a fibrin-specific agent plus a glycoprotein IIb/IIIa
nhibitor (median time from symptom onset to treatment of
.0 [2.2, 4.0] h for TMPG 0/1 vs. 2.8 [2.1, 3.8] h for
MPG 2/3; p  0.03; median time of 3.3 [2.3, 4.6] h for
atients with a closed artery vs. 2.8 [2.1, 3.9] h for open
rtery; p  0.001).
linical outcomes. Death at 30 days occurred more fre-
uently among patients who presented4 h from symptom
nset (Table 3, Fig. 7). The median time to treatment was
l
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.9 [2.1, 4.1] h; p  0.0001). There was no difference in
ates of recurrent myocardial infarction at 30 days by time to
igure 2. (A) Median time from symptom (sx) onset to treatment stratified b
0 min; (B) percent of patients with TMPG 2 or 3 at 60 min stratified by pre
rightness (gray scale) stratified by presentation 4 h from symptom onset v
igure 3. (A) Median time from symptom onset to treatment by Throm
atients with TFG 2 or 3 at 60 min stratified by presentation 4 h from
rame count stratified by presentation 4 h from symptom onset versus 4 hreatment, but congestive heart failure (CHF) tended to
ccur more frequently in patients who presented 4 h from
ymptom onset (Table 3). Similar results in outcomes were
rombolysis In Myocardial Infarction myocardial perfusion grade (TMPG) at
tion 4 h from symptom onset versus 4 h from symptom onset; (C) blush
4 h from symptom onset. DSA  digital subtraction angiography.
is In Myocardial Infarction flow grade (TFG) at 60 min; (B) percent of
om onset versus 4 h from symptom onset; (C) median corrected TIMIy Th
sentabolys
symptfrom symptom onset.
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escue/adjunctive PCI during the index catheterization (Ta-
le 3). In patients undergoing rescue/adjunctive PCI after
he initial angiogram, the median time to treatment among
atients who died by 30 days was 4.1 (2.3, 5.3) h vs. 2.8 (2.0,
.2) h for those who survived (p  0.004).
Similar findings of increased rates death or CHF by 30
able 2. Angiographic Characteristics and Time From
ymptom Onset to Treatment
Time to
Treatment
>4 h
(n  1,022)
Time to
Treatment
<4 h
(n  2,823) p Value
AD infarction 38.8% 34.3% 0.010
391/1,009 956/2,791
hrombus present 38.1% 38.8% 0.724
374/981 1,049/2,706
ollaterals present 16.1% 12.4% 0.004
150/930 316/2,546
alcified 7.7% 7.3% 0.656
68/880 174/2.394
isease extent 0.287
Single-vessel 44.9% 47.2%
Double-vessel 35.3% 35.0%
Triple-vessel 19.8% 17.8%
jection fraction 55.3 15.5, 58.8  14.5, 0.0001
n  495 n  1,360
rightness of blush on
digital subtraction
angiography, gray
scale
Median  6.6,
IQ 2.9/11,
n  213
Median  8.0,
IQ 3.5/12.6,
n  745
0.022
AD  left anterior descending.
igure 4. (A) Ejection fraction (%) stratified by presentation 4 h from
ymptom onset versus 4 h from symptom onset; (B) presence of
ollaterals (%) stratified by presentation 4 h from symptom onset versusp4 h from symptom onset.ays in patients with time from symptom onset to treatment
4 h were observed when restricted to the cohort of female
atients (n  851; 15.24% vs. 9.79%;p  0.021) or to the
ohort of male patients (n  2,974; 8.3% vs. 4.85%; p 
.001). Likewise, in patients who underwent rescue/
djunctive PCI after the initial angiogram, the rate of death
r CHF at 30 days was higher in patients with time from
ymptom onset to treatment 4 h when restricted to the
ubgroup of female patients (n  293; 19.09% vs. 9.84%; p
0.024) or to the subgroup of male patients (n  1,171;
.83% vs. 4.91%; p  0.002).
Median time to treatment was greater in patients who
ied at 30 days in analyses restricted to patients treated with
brin-specific agents only (t-PA, TNK, rt-PA; 2.8 [2.0,
.1] h vs. 3.3 [2.4, 4.7] h for fibrin-specific lyric alone, n 
,875; p  0.02) and among patients treated with a
ombination of fibrin-specific agents and glycoprotein IIb/
IIa inhibitors (2.9 [2.2, 4.1] h vs. 4.2 [2.7, 5.5] h for
ombination therapy, n  1,531; p  0.0001).
ISCUSSION
his analysis demonstrates that prolonged symptom-to-
reatment times are associated with impaired myocardial
erfusion grades as well as poorer epicardial flow grades
cross a variety of fibrinolytic regimens. The association
etween prolonged symptom-to-treatment times and im-
aired myocardial perfusion remained when adjusting for
picardial flow, infarct artery location, and other baseline
linical characteristics. After rescue/adjunctive PCI, myo-
ardial and epicardial perfusion remained poorer among
igure 5. Median time from symptom (sx) onset to treatment stratified by
ost-percutaneous coronary intervention (PCI) Thrombolysis In Myocar-
ial Infarction myocardial perfusion grade (TMPG).atients with prolonged symptom-to-treatment times. As in
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September 1, 2004:980–7 Duration of Symptoms and Myocardial Perfusionarlier studies (1–3), mortality rates were higher in patients
ith longer symptom-to-treatment times. This study ex-
ends these observations to demonstrate this association
ven among those patients who underwent rescue/
djunctive PCI.
In addition to confirming an association between pro-
onged symptom-to-treatment times and impaired epicar-
ial flow grades, this study extends previous observations to
emonstrate that prolonged symptom-to-treatment times
lso are associated with impaired myocardial perfusion
rades independent of epicardial flow. Impaired myocardial
erfusion after the administration of fibrinolytics has in turn
een associated with larger infarct sizes (17), worsened
yocardial salvage (5), and increased mortality (15,18)
mong STEMI patients. Prolonged symptom-to-treatment
imes also are associated with less-intense myocardial blush
n digital subtraction angiography, which could be specu-
ated to reflect a greater extent of myocardial and or
ndothelial edema in these patients. Similar observations
ere described in a recent study in which 24- to 36-h
T-segment resolution was worse among patients with
rolonged symptom-to-treatment times and correlated with
dverse clinical outcomes (19).
Although the association of prolonged duration of symp-
oms with adverse clinical outcomes is clear in studies of
brinolytic therapy, the same association is somewhat more
ontroversial among patients undergoing primary PCI
ather than fibrinolytic therapy (4,20–22). Although several
igure 6. (A) Median time from symptom onset to treatment stratified by p
ow grade (TFG); (B) percent of patients with open/closed epicardial arter
ymptom onset versus 4 h from symptom onset; (C) median correct
resentation 4 h from symptom onset versus 4 h from symptom onsetudies have observed no association between symptom-to- sreatment times and myocardial function (4) or clinical
utcomes (21) in patients undergoing primary PCI, a report
rom the Zwolle investigators that adjusted for baseline
linical and angiographic characteristics demonstrated a
ignificant and independent association between symptom-
o-treatment times and outcomes in high-risk patients and
n patients with closed epicardial arteries upon initial diag-
ostic angiography (23). In the present study, 30-day
ortality was significantly associated with a longer time
rom symptom onset to fibrinolytic treatment, even in
atients undergoing rescue/adjunctive PCI during the index
atheterization. Although this observation is retrospective,
t suggests that the higher risk conferred by a prolonged
ymptom-to-treatment time is not entirely offset by the
erformance of PCI after fibrinolytic therapy. The finding
f poorer myocardial perfusion and epicardial and flow after
escue/adjunctive PCI among patients with prolonged
ymptoms may also explain in part these patients’ poorer
linical outcomes.
Abnormal coronary flow after fibrinolytic administration
as been associated with increased mortality (24), and
revious studies have demonstrated that longer times from
ymptom onset to fibrinolytic treatment in STEMI may be
inked to reduced epicardial patency, particularly after treat-
ent with less fibrin-specific agents (1,25,26). Although
hese original observations were made in trials using strep-
okinase, subsequent studies of more fibrin-specific agents
ave demonstrated little or no association between
ercutaneous coronary intervention Thrombolysis In Myocardial Infarction
t-percutaneous coronary intervention stratified by presentation 4 h from
IMI frame count post-percutaneous coronary intervention stratified byost-p
y pos
ed Tymptom-to-treatment times and rates of epicardial patency
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ize in the present study was significantly greater, epicardial
ow grades were assessed in a core laboratory, and similar
ime dependency was observed among patients treated with
brin-specific, non-fibrin-specific, or “combination ther-
py” (fibrin-specific agent plus a glycoprotein IIb/IIIa in-
ibitor) regimens.
able 3. Clinical Outcomes at 30 Days and Time from
ymptom Onset to Treatment
Time to
Treatment
>4 h
(n  1,022)
Time to
Treatment
<4 h
(n  2,823) p Value
ll patients
Death 6.6% 3.3% 0.001
67/1,015 92/2,809
Recurrent MI 3.6% 3.4% 0.707
36/993 93/2,758
CHF 4.2% 3.1% 0.083
42/992 85/2,765
Death or MI 9.4% 6.3% 0.001
95/1,016 176/2,809
Death or CHF 10.1% 5.9% 0.001
103/1,016 165/2,809
Death, MI, or CHF 12.5% 8.7% 0.001
127/1,016 244/2,809
atients who underwent
rescue/adjunctive PCI
Death 7.6% 2.7% 0.001
31/405 29/1,059
Recurrent MI 2.5% 2.3% 0.793
10/395 24/1,045
CHF 5.3% 3.6% 0.143
21/393 38/1,048
Death or MI 9.4% 4.6% 0.001
38/405 49/1,059
Death or CHF 12.4% 5.8% 0.001
50/405 61/1,059
Death, MI, or CHF 13.6% 7.5% 0.001
55/405 79/1,059
HF  congestive heart failure; MI  myocardial infarction; PCI  percutaneous
oronary intervention.
igure 7. Clinical outcomes at 30 days stratified presentation 4 h from
ymptom onset versus4 h from symptom onset. CHF congestive heart
ailure; MI  myocardial infarction; OR  odds ratio.tudy limitations. This analysis was a non-randomized
etrospective analysis of pooled data from several clinical
rials and, as such, it is possible that both identified and
nidentified confounders may have influenced the out-
omes. Nonetheless, similar enrollment criteria were used in
ach of these trials, and outcomes were ascertained in a
linded fashion by a core laboratory. Because the analysis is
ased upon randomized trial data, the results observed here
ight not be applicable to all patients in clinical practice.
onclusions. Prolonged symptom-to-treatment times
mong STEMI patients are associated with impaired myo-
ardial perfusion independent of epicardial flow both im-
ediately after fibrinolytic administration and after rescue/
djunctive PCI. These data provide a pathophysiologic link
etween prolonged symptoms due to vessel occlusion, im-
aired myocardial perfusion, and poor clinical outcomes.
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